99 results about "Dl-Epinephrine" patented technology

A sterile storage stable ready-to-inject epinephrine composition contained within a flexible container and packaged within a secondary container, the composition including an aqueous pharmaceutically acceptable carrier containing epinephrine and a metal ion chelator, the epinephrine being present in a concentration of equal to or less than 0.07 mg / mL, substantially all of the epinephrine being an R-isomer, the composition having a pH of between 3.5-4.7, and the composition having, after storage of at least one month at 25° C., total impurities of equal or less than 0.7% and equal or less than 4% S-isomer content.

Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention provides an epinephrine automatic injection patch and method for cardiovascular first aid, and the injection patch comprises a flexible biosensing layer which obtains the subcutaneous impedance value and vital sign parameters of a patient; the microneedle array is used for adjusting the penetration depth based on the subcutaneous impedance value and controlling the deformation quantity through a piezoelectric actuator; the micro-fluidic pulse drug delivery module is connected with the micro-needle array and is used for executing pulse type drug injection according to the penetration depth; and the control module is used for judging an autonomous circulation recovery state based on the vital sign parameters and triggering the microfluidic pulse administration module to stop injection. According to the application, by constructing a first-aid closed loop of'multi-mode physical sign dynamic monitoring-self-adaptive microneedle administration-ROSC intelligent termination ', the response speed of epinephrine injection is increased, the bioavailability is improved, the risk of excessive medication is reduced, and the gold rescue efficiency and the neurological function prognosis rate of pre-hospital cardiac arrest patients are remarkably improved.

The disclosure herein relates to the innovative epinephrine formulations in aqueous solution of medicinal products that enhance the physicochemical stabilities of epinephrine and extend the product shelf life. In some instances, the formulations comprise epinephrine or a salt thereof, a complexing agent, and a “non-sulfite” antioxidant. The epinephrine formulations substantially demonstrated the superior physicochemical stabilities to conventional sulfite formulation of commercial medications currently available. In some instances, sulfite-free formulations further provide further benefit (e.g., safety benefits) to sulfite-sensitive patients. The compositions, methods for preparing the formulations, and methods of using the same (e.g., in the treatment of anaphylaxis) are also provided.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Pharmaceutical compositions having enhanced active component permeation properties are described.

The present invention discloses an injectable composition of epinephrine, their processes, and methods of treating hypotension.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The present invention discloses a method for simultaneously detecting dopamine and epinephrine, which comprises the following steps: 1) drawing a positive reduction peak current-dopamine concentration standard curve and a negative reduction peak current-dopamine and epinephrine total concentration standard curve; 2) after mixing the sample solution to be tested with a buffer solution, voltammetry detection is performed, the positive reduction peak current and the negative reduction peak current are tested, and then the concentration of dopamine is obtained by referring to the positive reduction peak current-dopamine concentration standard curve and the total concentration of dopamine and epinephrine is obtained by referring to the negative reduction peak current-dopamine and epinephrine total concentration standard curve, and then the concentration of dopamine is deducted from the total concentration of dopamine and epinephrine to obtain the concentration of epinephrine. The method of the present invention can realize the simultaneous determination of dopamine and epinephrine concentrations in biological samples, has the advantages of being simple and efficient, highly sensitive, and having strong anti-interference ability, and is suitable for on-site real-time detection.

The invention provides a liquid formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation invention includes ascorbic acid and / or a pharmaceutically acceptable salt thereof, an isotonicity agent, and has a pH of about 3.0-5.0. The liquid formulation according to the invention is stable and ready-to-administer.

The invention discloses a method for preparing phenylephrine hydrochloride genotoxic impurities, which comprises the following steps: by taking 3-hydroxyacetophenone as a starting material and copper bromide as a bromine source in isopropanol, reacting, and then preparing and separating to obtain dibromide impurities. The reaction condition for preparing the phenylephrine hydrochloride genotoxic impurity is mild, the operation is simple, the product purity is high, and the quality requirement for controlling phenylephrine hydrochloride can be met.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention relates to the field of pharmaceutical preparations, in particular to a prescription composition of an antioxidant-free epinephrine hydrochloride injection and a preparation method of the antioxidant-free epinephrine hydrochloride injection. The formula of the injection comprises epinephrine, sodium chloride, acetic acid, sodium acetate, hydrochloric acid and water for injection, and the pH value of the injection is 3.0-4.0. The preparation is simple in prescription composition, good in stability and higher in safety. The invention further provides a preparation method of the antioxidant-free epinephrine hydrochloride injection. The method is easy to operate, the residual oxygen content is controlled to be 2.0%-3.0%, terminal sterilization can be tolerated, the production cost is low, the requirements for equipment and preparation conditions are not high, and the antioxidant-free epinephrine hydrochloride injection is suitable for large-scale production.

The present application relates to the technical field of pharmaceutical preparation, and specifically discloses an adrenaline co-amorphous composition and a preparation method thereof, which aims at the problems of existing adrenaline, such as easy oxidative degradation, slow dissolution rate, poor storage stability, difficulty in forming stable amorphous by binary compounding of adrenaline and dexamethasone sodium phosphate, and complicated operation of multiple drug administration in clinic, and the present application prepares a ternary single-phase co-amorphous system by mixing adrenaline, ascorbic acid and dexamethasone sodium phosphate according to a molar ratio of 1:(0.1-1):1, and ascorbic acid is used as a molecular bridge to construct intermolecular interaction with an antioxidant stabilizer; during preparation, the raw materials are dissolved in water, reacted through water bath reaction, and then crude products are obtained through vacuum rotary evaporation or freeze-drying, and the finished products are obtained through vacuum drying to remove residual solvents. The composition has no crystal characteristic diffraction peak, a glass transition temperature of 70-90 DEG C, and greatly improved dissolution rate, chemical and physical stability, and the pharmacological synergy of the three components can reduce the side effects of first aid.

The utility model discloses a device for synthesizing phenylephrine hydrochloride and recovering a catalyst, which comprises a reaction kettle, a first plate-and-frame filter, a cleaning tank, a second plate-and-frame filter, a drying tank and a catalyst recovery tank which are communicated with one another, and a feed liquid outlet of the first plate-and-frame filter is communicated with a feed liquid temporary storage tank; a stirring device is arranged in the reaction kettle, the stirring device comprises a stirring shaft arranged in the reaction kettle and a stirring motor for driving the stirring shaft to rotate, stirring blades are arranged on the stirring shaft, an auxiliary stirring mechanism is arranged at the bottom of the stirring shaft, and the auxiliary stirring mechanism comprises a conical stirring cover arranged on the stirring shaft. A plurality of spiral turbulent flow fins are arranged on the outer side of the conical stirring cover in the circumferential direction; a steam coil pipe is arranged in the drying tank, and an air inlet of the steam coil pipe is communicated with a steam storage tank. According to the device, the catalyst in the reaction can be effectively recovered, waste liquid in the process is recycled, the energy consumption is low, the heat exchange effect is good, and the recovery efficiency of the catalyst is improved.

The utility model discloses epinephrine hydrochloride liquid medicine production equipment, and relates to the technical field of liquid medicine filling. Comprising a first nitrogen gas curtain arranged at a post-filling station, a preheating station and a wire drawing and sealing station respectively, the first nitrogen gas curtain is communicated with a nitrogen gas source, and the nitrogen gas source is communicated with a second nitrogen gas curtain and a feeding barrel; the second nitrogen gas curtain is arranged at the weighing station, and the feeding barrel is arranged at the liquid medicine filling station; the first nitrogen gas curtain is used for reducing residual oxygen in the ampoule bottle from operation after filling to operation before wire drawing and sealing; the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel; and the feeding barrel is used for batching under the protection of nitrogen. According to the utility model, the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel, and the feeding barrel is used for batching under the protection of nitrogen, so that the residual oxygen of raw materials is effectively reduced; and meanwhile, through the first nitrogen gas curtain, the time for exposing the ampoule bottle in the air is greatly shortened, and residual oxygen in the ampoule bottle which runs from the time after filling to the time before wire drawing and sealing is effectively reduced.

Pharmaceutical compositions including topical compositions of prodrugs are described, including prodrugs of epinephrine, which can be used to treat conditions relating to allergy, dermatology and immunology and the compositions having enhanced active component permeation properties are described.

An oral film comprising one or more layers wherein at least one layer contains epinephrine or a pharmaceutically acceptable salt thereof and at least one polymer, characterized in that said epinephrine is substantially insoluble in said at least one polymer. Process for the preparation of said oral film comprising the steps of: a) preparing a solution comprising said at least one polymer and a solvent in which epinephrine or a pharmaceutically acceptable salt thereof is substantially insoluble, (b) adding epinephrine, (c) spreading and drying the suspension obtained in step (b) in order to obtain a single-layer oral film, and the oral film is used as a medicament, and is used as a medicament in the treatment of allergic reactions.

The invention provides a novel method for preparing epinephrine, which comprises the following steps of: condensing catechol serving as an initial raw material with 2-(benzyl-methyl-amino) acetic acid to obtain 2-(benzyl methyl amino)-3 ', 4'-dihydroxyacetophenone hydrochloride, performing hydrogenation reduction to obtain racemic epinephrine, performing salification resolution with L-tartaric acid, and finally regulating the pH value to 8-9 by using ammonia water to obtain the epinephrine. According to the method, 2-(benzyl-methyl-amino) acetic acid is selected as a starting material instead of chloroacetic acid in a traditional process, and two steps of chloroacetylation and methylamine in the traditional process are combined into one step, so that the environmental problem caused by the use of chloroacetic acid and monomethylamine is avoided, the reaction steps are reduced, and the yield is increased; in addition, benzyl serving as a protecting group can be synchronously removed along with reduction of carbonyl in the catalytic reduction process, so that the risk caused by multi-step hydrogenation is avoided; and finally, the racemized isomer is obtained by recycling the resolution mother liquor and then salified with L-tartaric acid for resolution and recovery of the product, so that the yield is increased, the cost is reduced, and the method has excellent industrial production and application prospects.

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

The invention discloses a chemical mechanical polishing solution which comprises an epinephrine compound, the molecular structure of the epinephrine compound is # imgabs0 #, R1 is x, y-benzenediol or x, y, z-benzenediol, and x, y and z are numbers from 2 to 6; r2 and R3 are hydrogen atoms, alkane with the carbon number of 1-6 or alcohol with the carbon number of 1-6; and n is a number from 1 to 3. The invention provides a chemical mechanical polishing solution as well as a preparation method and application thereof, the polishing rate of silicon nitride can be inhibited while the polishing rate of the polishing solution to a silicon dioxide dielectric layer is increased, and the generation of dish-shaped grooves and scratches in the polishing process can be avoided or reduced.

Polymorphic forms of crystalline epinephrine malonate salt, including Form A, Form B, and Form C of crystalline epinephrine malonate salt. Also described are pharmaceutical compositions comprising one or more the polymorphic forms and methods for treating a patient comprising administering a pharmaceutical composition of one of the polymorphic forms of crystalline epinephrine malonate.

To provide pharmaceutical compositions excellent in anti-inflammatory activity.SOLUTION: Disclosed herein is a pharmaceutical composition comprising: (a) olopatadine or salt thereof; (b) belladonna or extract thereof, or tranexamic acid or salt thereof; and (c) one or more compounds selected from phenylephrine or salt thereof and glycyrrhizinic acid or salt thereof when the ingredient (b) is belladonna or extract thereof, or one or more compounds selected from phenylephrine or salt thereof, ephedrine or derivative or salt thereof and caffeine when the ingredient (b) is tranexamic acid or salt thereof.SELECTED DRAWING: None

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.

The invention discloses a preparation method of an epinephrine substance-loaded silk fibroin microneedle transdermal patch, which comprises the following steps: dissolving aminophenylboronic acid in a dimethyl sulfoxide aqueous solution to obtain an aminophenylboronic acid solution; adding the aminophenylboronic acid solution into a silk fibroin aqueous solution, then adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide, and uniformly mixing to obtain a reaction solution; after the reaction of the reaction solution is finished, dialyzing to remove the small molecule catalyst and dimethyl sulfoxide to obtain a first mixed solution; the method comprises the following steps: dissolving an epinephrine substance in deionized water to obtain an epinephrine substance solution; adding the epinephrine substance solution into the first mixed solution, and uniformly mixing to obtain a second mixed solution; and casting the second mixed solution into a microneedle mold, defoaming, and drying to obtain the adrenaline substance-loaded silk fibroin microneedle transdermal patch.

Provided are methods for determining the amount of one or more of one or more of norepinephrine (NE), epinephrine (E), and dopamine (D) in a sample using mass spectrometry. The methods generally involve ionizing one or more of NE (or derivatized NE), E (or derivatized E), and D (or derivatized D) in a sample and detecting and quantifying the amount of the ions to determine the amount of one or more of NE, E, and D in the sample.

The invention provides carbon-14-labeled epinephrine and a preparation method thereof, carbon-14-labeled noradrenaline and a preparation method thereof, and belongs to the field of radioactive chemistry. The invention provides a carbon-14 labeled epinephrine or a carbon-14 labeled noradrenaline, wherein the carbon-14 label is located at the a position of the benzene ring of the epinephrine or the noradrenaline. According to the present invention, the epinephrine and the noradrenaline are subjected to carbon-14 labeling, such that the metabolite ratio can be quantitatively analyzed, the dynamic conversion rule of the metabolite in the human body can be revealed, the drug administration scheme can be easily optimized, the toxicological mechanism can be easily clarified, the theoretical basis can be provided for the clinical safety application, and the scientific development of the first-aid drug can be promoted.